Dual role of deubiquitinating enzyme USP19 regulates mitotic progression and tumorigenesis by stabilizing survivin
- Authors
- Chandrasekaran, Arun Pandian; Tyagi, Apoorvi; Poondla, Naresh; Sarodaya, Neha; Karapurkar, Janardhan Keshav; Kaushal, Kamini; Park, Chang-Hwan; Hong, Seok-Ho; Kim, Kye-Seong; Ramakrishna, Suresh
- Issue Date
- Nov-2022
- Publisher
- CELL PRESS
- Citation
- MOLECULAR THERAPY, v.30, no.11, pp.3414 - 3429
- Indexed
- SCIE
SCOPUS
- Journal Title
- MOLECULAR THERAPY
- Volume
- 30
- Number
- 11
- Start Page
- 3414
- End Page
- 3429
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/172925
- DOI
- 10.1016/j.ymthe.2022.07.019
- ISSN
- 1525-0016
- Abstract
- Survivin is a component of the chromosomal passenger complex, which includes Aurora B, INCENP, and Borealin, and is required for chromosome segregation and cytokinesis. We performed a genome-wide screen of deubiquitinating enzymes for survivin. For the first time, we report that USP19 has a dual role in the modulation of mitosis and tumorigenesis by regulating survivin expression. Our results found that USP19 stabilizes and interacts with survivin in HCT116 cells. USP19 deubiquitinates survivin protein and extends its half-life. We also found that USP19 functions as a mitotic regulator by controlling the downstream signaling of survivin protein. Targeted genome knockout verified that USP19 depletion leads to several mitotic defects, including cytokinesis failure. In addition, USP19 depletion results in significant enrichment of apoptosis and reduces the growth of tumors in the mouse xenograft. We envision that simultaneous targeting of USP19 and survivin in oncologic drug development would increase therapeutic value and minimize redundancy.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의생명공학전문대학원 > 서울 의생명과학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/172925)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.